
|Videos|November 22, 2013
Targeting KRAS in Colorectal Cancer
Author(s)Charles S. Fuchs, MD, MPH
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting KRAS in colorectal cancer.
Advertisement
Clinical Pearls
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targetingKRASin colorectal cancer.
- KRASis mutated in 40% of patients and defines who should get cetuximab or panitumumab
- Patients should be genotyped for all mutations inKRASandNRAS
- Defining drug targets against mutantKRAShas been impossible thus far
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































